Live

Stocks are getting hit again as Trump lashes out at the Fed and Powell. See the latest.

Frankfurt - Delayed Quote EUR

MaxCyte, Inc. (MYE0.F)

2.1800

-0.1000

(-4.39%)

At close: April 17 at 3:29:02 PM GMT+2

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for MYE0.F

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)

Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)

With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns

With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns

Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround

Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround

MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know

MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know

MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Investors push MaxCyte (LON:MXCT) 9.7% lower this week, company's increasing losses might be to blame

Investors push MaxCyte (LON:MXCT) 9.7% lower this week, company's increasing losses might be to blame